Group One Trading’s ImmunityBio IBRX Stock Holding History

Group One Trading’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.5M	Buy	5,665,700 +4,245,600	+299%	+$29.1M	0.08%	226
2025 Q4	$2.81M	Sell	1,420,100 -73,300	-5%	-$166K	﹤0.01%	1977
2025 Q3	$3.67M	Buy	1,493,400 +320,000	+27%	+$824K	0.01%	1764
2025 Q2	$3.1M	Buy	1,173,400 +679,800	+138%	+$1.83M	0.01%	1725
2025 Q1	$1.49M	Sell	493,600 -702,700	-59%	-$2.13M	﹤0.01%	2092
2024 Q4	$3.06M	Sell	1,196,300 -525,700	-31%	-$2.19M	0.01%	1553
2024 Q3	$6.41M	Buy	1,722,000 +281,700	+20%	+$1.3M	0.02%	856
2024 Q2	$9.1M	Sell	1,440,300 -141,500	-9%	-$933K	0.04%	488
2024 Q1	$8.49M	Buy	1,581,800 +392,000	+33%	+$1.78M	0.03%	522
2023 Q4	$5.97M	Sell	1,189,800 -38,900	-3%	-$122K	0.02%	1003
2023 Q3	$2.08M	Sell	1,228,700 -256,400	-17%	-$515K	0.01%	1615
2023 Q2	$4.13M	Buy	1,485,100 +1,379,800	+1,310%	+$3.9M	0.01%	1111
2023 Q1	$192K	Sell	105,300 -38,500	-27%	-$120K	﹤0.01%	3720
2022 Q4	$729K	Buy	143,800 +36,100	+34%	+$198K	﹤0.01%	2701
2022 Q3	$535K	Sell	107,700 -32,000	-23%	-$146K	﹤0.01%	3164
2022 Q2	$520K	Buy	139,700 +38,200	+38%	+$153K	﹤0.01%	3381
2022 Q1	$569K	Buy	101,500 +12,700	+14%	+$77.9K	﹤0.01%	3673
2021 Q4	$540K	Sell	88,800 -89,900	-50%	-$675K	﹤0.01%	4046
2021 Q3	$1.74M	Buy	178,700 +24,800	+16%	+$273K	﹤0.01%	2807
2021 Q2	$2.2M	Sell	153,900 -46,900	-23%	-$775K	﹤0.01%	2536
2021 Q1	$4.77M	Sell	200,800 -23,800	-11%	-$617K	0.01%	1561
2020 Q4	$2.99M	Buy	224,600 +185,900	+480%	+$1.79M	0.01%	1705
2020 Q3	$268K	Sell	38,700 -136,700	-78%	-$1.36M	﹤0.01%	3414
2020 Q2	$2.15M	Buy	175,400 +156,000	+804%	+$881K	0.01%	1421
2020 Q1	$56K	Buy	19,400 +15,900	+454%	+$79.6K	﹤0.01%	3641
2019 Q4	$13K	Buy	+3,500	New	+$5.96K	﹤0.01%	4513
2019 Q2	–	Sell	-25,000	Closed	-$40K	–	5135
2019 Q1	$40K	Buy	+25,000	New	+$31.4K	﹤0.01%	3673
2018 Q2	–	Sell	-18,000	Closed	-$70K	–	5265
2018 Q1	$70K	Buy	18,000 +17,200	+2,150%	+$75.4K	﹤0.01%	3472
2017 Q4	$4K	Sell	800 -51,700	-98%	-$245K	﹤0.01%	4607
2017 Q3	$288K	Sell	52,500 -19,900	-27%	-$123K	﹤0.01%	2499
2017 Q2	$550K	Buy	+72,400	New	+$313K	0.01%	1909
2016 Q4	–	Sell	-78,800	Closed	-$613K	–	4592
2016 Q3	$613K	Buy	78,800 +55,200	+234%	+$412K	0.01%	1669
2016 Q2	$147K	Buy	23,600 +5,700	+32%	+$44.2K	﹤0.01%	2609
2016 Q1	$147K	Buy	17,900 +10,600	+145%	+$99.9K	﹤0.01%	2537
2015 Q4	$127K	Buy	7,300 +6,500	+813%	+$96.4K	﹤0.01%	2833
2015 Q3	$9K	Buy	+800	New	+$17.5K	﹤0.01%	4336

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Group One Trading's IBRX Position: Q1 2026 in Review

Group One Trading sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 766,908 shares — an estimated $5.25M sold.

Group One Trading first reported a position in IBRX in Q4 2015 and held it in 25 quarters. The position peaked at $4.05M in Q1 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Group One Trading reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
Group One Trading sold 766,908 ImmunityBio shares in Q1 2026, an estimated $5.25M.
Group One Trading first reported a position in ImmunityBio in Q4 2015 and held it in 25 quarters.
Group One Trading's ImmunityBio position peaked at $4.05M in Q1 2025.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.